423P Safety and efficacy of delandistrogene moxeparvovec versus placebo in Duchenne muscular dystrophy: phase 3 EMBARK primary results

• DOI: 10.1016/j.nmd.2024.07.303
• Publication Date: 2024-10-04T06:53:18Z
• Authors: J. Mendell; F. Muntoni; C. McDonald; E. Mercuri; E. Ciafaloni; H. Komaki; C. Leon-Astudillo; A. Nascimento; C. Proud; U. Schara-Schmidt; A. Veerapandiyan; C. Zaidman; A. Murphy; C. Reid; D. Asher; E. Darton; S. Mason; P. Fontoura; J. Elkins; L. Rodino-Klapac